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Abstract
Background: To evaluate the long-term efficacy, safety and immunogenicity of continuing LBEC0101; the
etanercept (ETN) biosimilar; or switching from the ETN reference product (RP) to LBEC0101 in patients with
rheumatoid arthritis (RA).
Methods: This multicentre, single-arm, open-label extension study enrolled patients who had completed a 52-week
randomised, double-blind, parallel phase III trial of LBEC0101 vs ETN-RP. Patients treated with ETN-RP during the
randomised controlled trial switched to LBEC0101; those treated with LBEC0101 continued to receive LBEC0101 in
this study. LBEC0101 (50 mg) was administered subcutaneously once per week for 48 weeks with a stable dose of
methotrexate. Efficacy, safety and immunogenicity of LBEC0101 were assessed up to week 100.
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Results: A total of 148 patients entered this extension study (70 in the maintenance group and 78 in the switch
group). The 28-joint disease activity scores (DAS28)-erythrocyte sedimentation rate (ESR) were maintained in both
groups from week 52 to week 100 (from 3.068 to 3.103 in the maintenance group vs. from 3.161 to 3.079 in the
switch group). ACR response rates at week 100 for the maintenance vs. switch groups were 79.7% vs. 83.3% for
ACR20, 65.2% vs. 66.7% for ACR50 and 44.9% vs. 42.3% for ACR70. The incidence of adverse events and the
proportion of patients with newly developed antidrug antibodies were similar in the maintenance and switch
groups (70.0% and 70.5%, 1.4% and 1.3%, respectively).
Conclusions: Administration of LBEC0101 showed sustained efficacy and acceptable safety in patients with RA after
continued therapy or after switching from ETN-RP to LBEC0101.
Trial registration: ClinicalTrials.gov, NCT02715908. Registered 22 March 2016.
Keywords: Etanercept, LBEC0101, Rheumatoid arthritis, Biosimilar, Switch
Background
The use of biologic disease-modifying anti-rheumatic
drugs (bDMARDs) has contributed markedly to the im-
provement in the treatment of rheumatoid arthritis (RA)
[1]. Indeed, the level of a country’s use of bDMARDs ap-
pears to correlate with its control rates of RA [2]. While
the reasons for this are complex, access to biologics is
important in the ongoing management of RA. However,
the cost of some bDMARDs has limited their availability
and contributed to restrictive policies around their use
[3, 4]. Biosimilars, which are similar but not identical to
their innovator bDMARDs, have a cost advantage over
innovator products for individuals and healthcare sys-
tems, and this may help improve access to therapy [5, 6].
Tumour necrosis factor (TNF)-inhibitors including
etanercept (ETN) are effective for the treatment of RA
[7], with TNF-α being a well-recognised contributor to
the inflammatory changes that occur in RA [8, 9]. ETN
was the first approved bDMARD for the treatment of
RA [10, 11], and its biosimilar, LBEC0101, was recently
approved in Korea (Eucept®) and Japan (Etanercept BS
“MA”) in 2018 for the treatment of the same indications
as ETN, including RA [12, 13].
Biosimilarity in terms of pharmacokinetics, efficacy
and safety should be demonstrated according to the
guidelines of regulatory agencies [14, 15]. While estab-
lishing the efficacy and safety of long-term use of biosi-
milars or that of switching from reference product (RP)
to biosimilars is not mandatory for regulatory processes,
it is very important to examine these parameters in clin-
ical settings for prescribing doctors and patients. Indeed,
clinical trials of several biosimilars have shown promis-
ing results in terms of long-term efficacy and safety,
confirming their potential as an alternative to branded
products in patients with RA [16–21].
The pharmacokinetics of LBEC0101 and ETN-RP in
healthy male volunteers were similar [22], and the effi-
cacy and safety of LBEC0101 were equivalent to ETN
after 52 weeks of treatment in a phase III, randomised,
double-blind, parallel-group study [23]. This study was
an open-label extension trial of the phase III study [23]
and investigated the long-term efficacy, safety and im-
munogenicity of treatment with LBEC0101 in Korean
patients with RA who continued therapy or were
switched from ETN-RP to LBEC0101 at the end of the
randomised phase of the trial.
Methods
Study design
This was a 48-week multicentre, single-arm, open-label
extension study conducted at 28 centres in Korea, follow-
ing a phase III, multicentre, randomised, double-blind,
parallel-group study conducted in Korea and Japan [23].
The study received institutional review board approvals,
and all procedures were carried out in accordance with
the ethical principles of the Declaration of Helsinki and
Good Clinical Practice. All patients gave written informed
consent prior to inclusion in the study. This study was
registered at ClinicalTrials.gov (NCT02715908).
Patients
Patients who had completed treatment in the preceding
randomised double-blind study [23] and required pro-
longed treatment for RA at the investigators’ discretion
were eligible for the extension study. The inclusion
criteria for the preceding randomised double-blind study
have been previously reported [23].
Patients deemed unable to participate in the extension
study because of adverse events (AEs) in the preceding
randomised double-blind study or who had ≥ 10 swollen
joints (out of the total 66 assessed joints), had ≥ 12 ten-
der joints (out of the total 68 assessed joints), or were
pregnant or lactating at the time of the study were
excluded. Additional details of exclusion criteria have
been reported in the preceding randomised double-blind
study [23].
Park et al. Arthritis Research & Therapy          (2019) 21:122 Page 2 of 11
Drug treatments
In the extension study, all patients self-administered
LBEC0101 (50 mg) subcutaneously once per week for an
additional 48 weeks, with a 2-week post-treatment
follow-up. The needle size of the LBEC0101 pre-filled
syringe was changed from 27G in the preceding rando-
mised double-blind study (LG-ECCL002) to 29G in this
extension study. The maintenance group included
patients who had received LBEC0101 in the preceding
randomised double-blind study and continued to receive
LBEC0101 in this extension study, and the switch group
included patients who had received ETN-RP in the pre-
ceding randomised double-blind study. All patients
received concomitant methotrexate (MTX) at a stable
dose (7.5–15 mg/week). Stable dosages of nonsteroidal
anti-inflammatory agents, analgesics and oral/suppository/
topical/bronchial/nasal corticosteroids (≤ 10mg/day pred-
nisone equivalent dose) were also permitted. No DMARDs
other than MTX and no intravenous, intramuscular,
intra-articular or epidural corticosteroids were allowed.
Efficacy
The efficacy assessments were mean changes in 28-joint
disease activity scores (DAS28)-erythrocyte sedimenta-
tion rate (ESR) and DAS28-serum C-reactive protein
(CRP) from weeks 0 and 52, as a baseline, to weeks 76
and 100; American College of Rheumatology (ACR)20,
ACR50 and ACR70 response rates at weeks 52, 76 and
100 from week 0; remission rate (i.e., DAS28-ESR < 2.6)
at weeks 52, 76 and 100; and rate of European League
Against Rheumatism (EULAR) response on DAS28-ESR
at weeks 52, 76 and 100 compared with week 0.
Safety
The incidence of AEs and serious AEs (SAEs) were eval-
uated up to week 102. AEs of special interest that were
known as key safety issues for ETN-RP (i.e., infections,
sepsis, injection site reactions, malignancies, heart fail-
ure, neurological events, tuberculosis, hepatitis B reacti-
vation and interstitial lung disease) were specifically
investigated. AEs were coded using MedDRA V.19.0.
Immunogenicity
Antidrug antibodies (ADAs) and neutralising antibodies
at weeks 52, 76 and 100 were analysed by validated
electrochemiluminescent immunoassay using Meso
Scale Discovery platform (Meso Scale Diagnostics, Rock-
ville, MD, USA). Biotinylated LBEC0101 and SULFO-
TAG-labelled LBEC0101 were used to detect ADAs. A
neutralising antibody test was performed using biotinyl-
ated LBEC0101 and SULFO-TAG-labelled TNF-alpha
only when the results were positive for ADAs.
Statistical analysis
Efficacy analyses were performed on the full analysis set
(FAS), defined as all randomised patients who received
the investigational product at least once in the extension
study and had at least one DAS28-ESR measurement
after week 52. All safety analyses were performed on the
safety set, which consisted of all randomised patients
who received the investigational product at least once in
the extension study and completed at least one safety
assessment. The primary efficacy endpoint was analysed
using analysis of covariance (ANCOVA) with treatment
group assigned in the preceding randomised double-
blind study and previous use of bDMARDs as fixed fac-
tors and week 0 DAS28-ESR score as a covariate. The
least square (LS) mean and 95% confidence interval (CI)
adjusted by ANCOVA were presented. Missing data
were handled using last observation carried forward
analysis. Statistical analyses were conducted using SAS
version 9.3 (SAS Institute, Cary, NC, USA).
Results
Patient disposition and baseline characteristics
The study flow chart is shown in Fig. 1. Of the 156
Korean patients who completed the preceding rando-
mised double-blind study, 148 participated in the exten-
sion study (70 in the maintenance group and 78 in the
switch group). One patient failed to complete the
post-week 52 DAS28-ESR assessments, leaving 69
patients in the maintenance group and 78 in the switch
group included in the FAS.
Characteristics of the FAS at week 0 and week 52 are
shown in Table 1. Korean and Japanese patients had a
similar disposition in both the LBEC0101 and ETN-RP
groups in the preceding, randomised, double-blind study
[23]. Although only Korean patients were included in
the present study, there were no notable differences in
the disposition or RA characteristics between groups at
weeks 0 and 52. Both Korean and Japanese patients
responded similarly to LBEC0101 and ETN-RP up to
week 52; the similarities in RA characteristics were
maintained up to week 52 and remained well-balanced
between the two groups.
Efficacy
During the preceding randomised, double-blind study,
efficacy endpoints, including DAS28-ESR and DAS28-
CRP scores and ACR response rate, were improved in
both the ETN-RP and LBEC0101 groups; the improve-
ments were comparable between the groups at week 52.
Improvements in the DAS28-ESR score from week 52
were well maintained throughout this extension phase in
both the maintenance and switch groups (Fig. 2): at
week 100, the LS mean changes (95% CI) from week 52
were − 0.052 (− 0.314, 0.210) in the maintenance group
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and − 0.149 (− 0.417, 0.119) in the switch group (estimated
treatment difference between groups 0.097 [95% CI −
0.200, 0.393]). At week 100, the corresponding LS mean
changes (95% CI) from week 0 were − 3.262 (− 3.567, −
2.957) and − 3.313 (− 3.625, − 3.001) in each group, re-
spectively (estimated treatment difference between groups
0.051 [95% CI − 0.294, 0.395]). The changes in
DAS28-CRP score from week 52 to week 100 were also
small (LS mean changes 0.240 and 0.138 in the mainten-
ance and switch groups, respectively), indicating that effi-
cacy at week 52 was sustained at week 100.
The ACR20, ACR50 and ACR70 response rates at weeks
52, 76 and 100 are shown in Fig. 3a–c, with no statistically
significant differences between the maintenance and
switch groups found for any of the results. The improve-
ments in ACR response rates were sustained from week
52 to week 100. The ACR20, ACR50 and ACR70 rates at
week 100 based on week 0 were 79.7%, 65.2% and 44.9%,
respectively, in the maintenance group, and 83.3%, 66.7%
and 42.3% in the switch group.
At weeks 52 and 100, the remission rates based on
DAS28-ESR < 2.6 in the FAS were 43.5% (30/69) and
36.2% (25/69), respectively, in the maintenance group,
while corresponding rates in the switch group were
25.6% (20/78) and 33.3% (26/78). The decrease in the
proportion of patients in remission from week 52 to
week 100 in the maintenance group was not statistically
significant. The rates of EULAR response on DAS28-
Fig. 1 Patient flow chart: Randomisation was carried out in the initial randomised trial only (1:1 ratio to LBEC0101 or ETN-RP), and no further
randomisation was carried out in the extension study. *The number of patients enrolled in the extension study is different from the number
finishing the phase III study because only Korean patients were enrolled in the extension study. ETN-RP, etanercept reference product
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Table 1 Baseline patient demographic and disease characteristics at week 0 and week 52 (full-analysis set)
Demographic variable Maintenance group (n = 69) Switch group (n = 78) Overall (n = 147)
Age, years 52.6 ± 11.0 54.5 ± 11.0 53.6 ± 11.0
Female, n (%) 52 (75.4) 69 (88.5) 121 (82.3)
Weight, kg 59.9 ± 11.6 57.2 ± 9.6 58.5 ± 10.7
Functional status in RA, n (%)
I 11 (15.9) 15 (19.2) 26 (17.7)
II 50 (72.5) 45 (57.7) 95 (64.6)
III 8 (11.6) 18 (23.1) 26 (17.7)
IV 0 0 0
Time since RA diagnosis, years 8.1 ± 8.4 7.9 ± 7.8 8.0 ± 8.1
Previous use of biologics, n (%)
Week 0† 11 (15.9) 8 (10.3) 19 (12.9)
MTX dose, mg/week
Week 52 12.6 ± 2.7 12.6 ± 2.7 12.6 ± 2.7
Baseline corticosteroids, n (%)
Week 0† 57 (82.6) 70 (89.7) 127 (86.4)
Positive rheumatoid factor test result, n (%)
Week 0† 48 (69.6) 52 (66.7) 100 (68.0)
Tender joint count from 68 joints
Week 0† 18.4 ± 9.83 18.9 ± 10.68 18.7 ± 10.26
Week 52 1.9 ± 2.48 2.2 ± 2.60 2.0 ± 2.54
Tender joint count from 28 joints
Week 0† 11.5 ± 5.90 11.5 ± 5.76 11.5 ± 5.81
Week 52 1.3 ± 1.83 1.4 ± 1.91 1.3 ± 1.87
Swollen joint count from 66 joints
Week 0† 13.2 ± 8.09 13.5 ± 7.94 13.4 ± 7.98
Week 52 1.0 ± 1.58 1.3 ± 2.04 1.2 ± 1.84
Swollen joint count from 28 joints
Week 0† 9.1 ± 5.42 9.1 ± 5.45 9.1 ± 5.42
Week 52 0.7 ± 1.21 0.9 ± 1.46 0.8 ± 1.34
DAS28-ESR
Week 0† 6.300 ± 0.8949 6.343 ± 0.9170 6.323 ± 0.9039
Week 52 3.068 ± 1.0238 3.161 ± 0.9745 3.117 ± 0.9956
ESR, mm/hour
Week 0† 51.3 ± 21.75 58.4 ± 26.73 55.1 ± 24.69
Week 52 25.4 ± 15.66 29.3 ± 20.88 27.5 ± 18.65
CRP, mg/dL
Week 0† 1.22 ± 1.341 1.52 ± 2.152 1.38 ± 1.818
Week 52 0.20 ± 0.364 0.34 ± 0.770 0.28 ± 0.616
HAQ-DI
Week 0† 1.627 ± 0.7281 1.458 ± 0.7736 1.537 ± 0.7548
Week 52 0.792 ± 0.8241 0.840 ± 0.7972 0.817 ± 0.8075
PtAP
Week 0† 71.67 ± 20.203 65.46 ± 21.722 68.37 ± 21.182
Week 52 21.43 ± 19.788 25.62 ± 22.269 23.66 ± 21.173
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ESR at weeks 52 and 100 are shown in Fig. 4. The rates
of EULAR response and the shift rate of EULAR activity
between the two groups were similar.
There were no statically significant differences be-
tween the two groups in any of the efficacy results.
Safety
In the preceding randomised, double-blind study, 90%
and 89.7% of patients in the maintenance and switch
groups, respectively, reported AEs, and during the exten-
sion study, 70.0% and 70.5%, respectively, reported AEs.
The overall incidences were 95.7% and 96.2%, respect-
ively, during the entire 100-week study period.
A summary of AEs occurring in the extension study,
including AEs experienced by ≥ 5%, is provided in
Table 2, with the most common being upper respiratory
tract infection, nasopharyngitis and arthralgia. The inci-
dences of SAEs, ADRs, serious ADRs and AEs leading to
discontinuation or drug interruption are also shown in
Table 2, and all were similar between the two groups.
Most AEs during the extension study were mild in sever-
ity in both groups, and no deaths occurred. SAEs that
occurred in more than one patient during the extension
study were acute pyelonephritis (two patients; 1.4%) and
arthralgia (two patients; 1.4%). The most frequent AEs
and ADRs of special interest were infections and infesta-
tions, with no notable differences between the groups. In
the preceding randomised double-blind study, injection
site reactions were experienced by 23 patients (29.5%),
with a total of 164 reactions, in the switch group and by
10 patients (14.3%), with a total of 27 reactions, in the
maintenance group. In the present extension study, five
Table 1 Baseline patient demographic and disease characteristics at week 0 and week 52 (full-analysis set) (Continued)
Demographic variable Maintenance group (n = 69) Switch group (n = 78) Overall (n = 147)
PtGADA
Week 0† 69.52 ± 21.619 66.58 ± 20.306 67.96 ± 20.912
Week 52 28.09 ± 23.129 26.71 ± 22.575 27.36 ± 22.769
PhGADA
Week 0† 76.09 ± 14.748 69.12 ± 17.170 72.39 ± 16.400
Week 52 18.16 ± 13.625 16.49 ± 12.324 17.27 ± 12.933
Data are presented as mean ± standard deviation, or number of patients (%)
†Week 0 data are given for the population of the extension study only (maintenance group, n = 69/switch group, n = 78)
CRP C-reactive protein, DAS28-ESR disease activity score in 28 joints based on erythrocyte sedimentation rate, ESR erythrocyte sedimentation rate, HAQ-DI Health
Assessment Questionnaire Disability Index, MTX methotrexate, PhGADA physician’s global assessment of disease activity, PtAP patient’s assessment of arthritis pain,
PtGADA patient’s global assessment of disease activity, RA rheumatoid arthritis
Fig. 2 Disease activity score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) (full-analysis set). DAS28-ESR mean values at weeks
0, 52, 76 and 100. SE, standard error
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patients (6.4%), with a total of 10 reactions, in the switch
group and one patient (1.4%), with a total of one reac-
tion, in the maintenance group experienced injection site
reactions. Of these, five had experienced similar reac-
tions in the preceding study and one patient in the
switch group experienced an injection site reaction for
the first time. There were no neurologic events, or cases
of heart failure, hepatitis B reactivation, sepsis or inter-
stitial lung disease reported in either group during the
extension study.
Immunogenicity
At the end of the preceding randomised double-blind
study (week 52), two (2.9%) and 11 (14.1%) patients in the
maintenance and switch groups, respectively, had positive
ADA tests, with positive neutralising antibody occurring
in one (1.3%) patient in the switch group. During the ex-
tension study, one patient in the maintenance group
(1.4%) and one patient in the switch group (1.3%) had new
positive ADA test results. No patients had new positive
neutralising antibody during the extension study. The
Fig. 3 ACR response rates (full-analysis set). a ACR20, b ACR50 and c ACR70 response rates at weeks 52, 76 and 100. ACR, American College of
Rheumatology; CI, confidence interval
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immunogenicity results for the different study periods are
shown in Additional file 1: Table S1.
Discussion
This open-label extension study evaluated the long-term
efficacy, safety and immunogenicity of LBEC0101 in Ko-
rean patients with RA who were previously treated with
ETN-RP or LBEC0101 for 52 weeks during a phase III,
randomised, double-blind study which included both
Korean and Japanese patients. We compared clinical
parameters for up to 100 weeks in patients who either
continued LBEC0101 or switched from ETN-RP to
LBEC0101 after completion of the preceding study.
Equivalent efficacy and comparable safety profiles for
LBEC0101 and ETN-RP were demonstrated in the
52-week study [23]. The improvements in DAS28-ESR,
DAS28-CRP and ACR response rate shown during the
preceding study were sustained in both the maintenance
and switch groups, and similar proportions of patients in
both groups achieved a good or moderate EULAR re-
sponse and remission. Overall, these results confirm that
the efficacy previously shown for LBEC0101 extended to
week 100 and that efficacy was maintained for patients
who switched to LBEC0101 from ETN-RP.
The safety profile was maintained with no notable dif-
ferences between groups and no new safety concerns.
Regarding AEs of special interest, no neurologic events,
cases of heart failure, hepatitis B reactivation, sepsis, or
interstitial lung disease were reported in either group.
Latent TB was confirmed but there were no cases of
active TB and no notable between-group differences in
AEs of known key ETN-RP safety issues.
Fig. 4 EULAR response rates (full analysis set). EULAR response rates at weeks 52, 76 and 100. EULAR, European League Against Rheumatism
Table 2 Adverse events during the extension study (safety analysis set)
Maintenance group (n = 70) Switch group (n = 78)
Number % Number %
All AEs 49 70.0 55 70.5
All ADRs 20 28.6 26 33.3
Serious AEs 6 8.6 8 10.3
Serious ADRs 3 4.3 4 5.1
Any AEs leading to discontinuation 1 1.4 3 3.8
Any AEs leading to temporary drug interruption 13 18.6 8 10.3
AEs experienced by ≥ 5% of patients in either group (by preferred term)
Upper respiratory tract infection 4 5.7 9 11.5
Nasopharyngitis 7 10.0 4 5.1
Arthralgia 3 4.3 8 10.3
Cough 3 4.3 4 5.1
Active tuberculosis 0 0 0 0
Injection site reaction 1 1.4 5 6.4
ADR adverse drug reaction, AE adverse event
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The incidence of injection site reactions was lower
than that in the preceding study, which may be attribut-
able to the reduced injection needle size used in the ex-
tension study [24, 25]. Most injection site reactions in
the ETN-RP group of the preceding study occurred in
the early stage of the treatment period. However, in the
extension study, the incidence in the switch group was
low in the early stage after the switch, suggesting that
ETN-RP and LBEC0101 are similar in this regard. One
important factor to consider is whether switching in-
creases the risk of ADA, which can lead to immuno-
logical reactions and decreased drug efficacy [26]. One
patient in each group had new positive ADA test results
and the incidence of ADA rarely increased after week 52
(Additional file 1: Table S1), demonstrating that no new
immunogenicity concerns arose after the switch.
Several studies have documented continued efficacy
and safety after switching from RPs to biosimilars, and
after long-term treatment [18–21]. In a study by Emery
et al. [18], patients received the ETN biosimilar SB4 for
48 weeks in an open-label extension after an initial
52-week randomised controlled trial of SB4 or ETN.
Efficacy and safety were maintained until week 100 in
both the maintenance and switch groups. The PLANE-
TRA extension study reported that switching from the
infliximab RP to CT-P13 did not decrease efficacy or
change the safety profile [20]. In a study comparing
adalimumab and its biosimilar SB5, efficacy and safety
were maintained after switching, albeit after a shorter
overall duration of treatment (52 weeks vs 100 weeks in
our study) [19].
A lower than expected retention rate has been observed
in RA patients switched from the infliximab RP to
CT-P13 in recent open-label [27] and real-life [28] switch
studies and is thought to be attributable to the nocebo
effect. The results of the present extension study provide
no evidence for the nocebo effect, as the discontinuation
rate in the switch group was not higher than that in the
maintenance group (7.7% and 14.3%, respectively).
Key limitations were that the assessment was only
conducted up to week 100 and that only the Korean pa-
tients were included. Therefore, efficacy and safety for
longer-term usage or in other ethnic populations should
be evaluated in post-marketing surveillance studies. It
should also be noted that the data from our study were
analysed and presented as grouped patients; variations in
efficacy may occur, meaning that the results of this study
may not apply to each individual patient.
Both the efficacy and safety of switching to LBEC0101
need to be confirmed during post-marketing surveil-
lance. Our study only included patients who continued
LBEC0101 or switched from ETN-RP to LBEC0101. Bio-
similars are only considered interchangeable when it is
shown that the risk of diminished safety and efficacy
when switching is not greater than when the RP is used
alone. Additionally, US FDA guidelines state that switch-
ing studies should evaluate switching between inter-
changeable medications two or more times [26, 29].
Therefore, further studies that include patients who have
undergone two or more switching intervals are required.
Recent consensus-based recommendations for biosimilar
treatment of rheumatological diseases recommend con-
tinued monitoring of their safety and efficacy by asses-
sing data from multiple biosimilar/RP switches [30].
Conclusions
In conclusion, long-term administration of LBEC0101 was
associated with ongoing efficacy in patients with RA.
Patients who switched from ETN-RP at the end of the
preceding randomised double-blind study showed persist-
ent efficacy of therapy after switching to LBEC0101.
LBEC0101 was well tolerated in both the maintenance
and switch groups, with no new safety concerns identified.
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